NCT04455230View on ClinicalTrials.gov

A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions
Fabry DiseaseLysosomal Storage Diseases
Interventions
GENETIC

FLT190

FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).

Trial Locations (2)

Unknown

Charité - Universitätsmedizin Berlin, Berlin

Royal Free London, London

Sponsors

Lead Sponsor

Spur Therapeutics
All Listed Sponsors
lead

Spur Therapeutics

INDUSTRY

NCT04455230 - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 | Biotech Hunter | Biotech Hunter